Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked conscientiously but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. The first CytoDyn article of mine, “CytoDyn: What To Do When It is Too Good To Be True?”, set away what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire job interview which I came away with an inadequate opinion of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, though the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and associated intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) and the first new drug application approval ($five million), and also royalty payments of five % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it has this single therapy as well as a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Might all this be smoke and mirrors? That is a question I’ve been asking myself with the really start of the interest of mine in this company. Judging with the multiples of a huge number of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some might say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *